Bristol-Myers shareholders back the big Celgene buyout. What happens now?
Even though its lead investor sided with the activists in opposing the move, the shareholders at Bristol-Myers Squibb have provided a lopsided vote in favor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
